- Home
- JNJ
as of 02-27-2026 3:49pm EST
$248.37
+$4.90
+2.01%
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | 589.2B | IPO Year: | 2003 |
| Target Price: | $227.29 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 11.03 | EPS Growth: | 90.50 |
| 52 Week Low/High: | $141.50 - $247.25 | Next Earning Date: | 04-21-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6.63% | Revenue Growth (next year): | 7.21% |
| P/E Ratio: | 22.07 | Index: | |
| Free Cash Flow: | 19.7B | FCF Growth: | -5.53% |
AI-Powered JNJ Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 75.90%
75.90%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
Schmid Timothy
Sell
EVP, WW Chair, MedTech
JNJ Feb 20, 2026
Avg Cost/Share
$245.66
Shares
1,322
Total Value
$324,762.52
Owned After
25,447
SEC Form 4
Schmid Timothy
Sell
EVP, WW Chair, MedTech
JNJ Feb 18, 2026
Avg Cost/Share
$244.37
Shares
22,623
Total Value
$5,527,505.94
Owned After
25,447
Broadhurst Vanessa
Sell
EVP, Global Corp Affairs
JNJ Feb 17, 2026
Avg Cost/Share
$243.39
Shares
12,394
Total Value
$3,016,575.66
Owned After
23,003
REED JOHN C
Sell
EVP, Innovative Medicine, R&D
JNJ Feb 17, 2026
Avg Cost/Share
$243.00
Shares
53,931
Total Value
$13,105,233.00
Owned After
12,941
Wolk Joseph J
Sell
Exec VP, CFO
JNJ Feb 17, 2026
Avg Cost/Share
$242.82
Shares
89,654
Total Value
$21,767,826.99
Owned After
14,000
Swanson James D.
Sell
EVP, CIO
JNJ Feb 17, 2026
Avg Cost/Share
$242.70
Shares
20,521
Total Value
$4,980,446.70
Owned After
25,698.131
SEC Form 4
Swanson James D.
Sell
EVP, CIO
JNJ Feb 13, 2026
Avg Cost/Share
$243.74
Shares
41,559
Total Value
$10,129,312.29
Owned After
25,698.131
Duato Joaquin
Sell
CEO and Chairman of the Board
JNJ Jan 26, 2026
Avg Cost/Share
$221.24
Shares
100,000
Total Value
$22,122,893.44
Owned After
79,634
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Schmid Timothy | JNJ | EVP, WW Chair, MedTech | Feb 20, 2026 | Sell | $245.66 | 1,322 | $324,762.52 | 25,447 | |
| Schmid Timothy | JNJ | EVP, WW Chair, MedTech | Feb 18, 2026 | Sell | $244.37 | 22,623 | $5,527,505.94 | 25,447 | |
| Broadhurst Vanessa | JNJ | EVP, Global Corp Affairs | Feb 17, 2026 | Sell | $243.39 | 12,394 | $3,016,575.66 | 23,003 | |
| REED JOHN C | JNJ | EVP, Innovative Medicine, R&D | Feb 17, 2026 | Sell | $243.00 | 53,931 | $13,105,233.00 | 12,941 | |
| Wolk Joseph J | JNJ | Exec VP, CFO | Feb 17, 2026 | Sell | $242.82 | 89,654 | $21,767,826.99 | 14,000 | |
| Swanson James D. | JNJ | EVP, CIO | Feb 17, 2026 | Sell | $242.70 | 20,521 | $4,980,446.70 | 25,698.131 | |
| Swanson James D. | JNJ | EVP, CIO | Feb 13, 2026 | Sell | $243.74 | 41,559 | $10,129,312.29 | 25,698.131 | |
| Duato Joaquin | JNJ | CEO and Chairman of the Board | Jan 26, 2026 | Sell | $221.24 | 100,000 | $22,122,893.44 | 79,634 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Motley Fool
Middleby Is Spinning Off Its Food Processing Segment After a $540 Million Asset Sale. Can the Breakup Close Its Valuation Gap?
📊
AI Sentiment
Positive
7/10
Insider Monkey
Is Blackstone Inc. (BX) One of the Best Cheap Blue Chip Stocks to Buy According to Analysts?
📈
AI Sentiment
Highly Positive
8/10
Simply Wall St.
Is It Too Late To Consider Johnson & Johnson (JNJ) After Its Strong 1 Year Rally?
📈
AI Sentiment
Highly Positive
9/10
Zacks
Johnson & Johnson (JNJ) Advances While Market Declines: Some Information for Investors
📊
AI Sentiment
Positive
6/10
Investor's Business Daily
These Stocks Lead Dow Jones In February. Hint: It's Not AI Companies.
➖
AI Sentiment
Neutral
4/10
Zacks
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold?
📈
AI Sentiment
Highly Positive
8/10
Motley Fool
2 Reasons I'd Happily Hold Johnson & Johnson Through Any Market Crash
📈
AI Sentiment
Highly Positive
8/10
Compare JNJ vs Leading Stocks
See how JNJ stacks up against similar companies in the market
Head-to-Head Comparisons
More Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.